Vogenx clinical trials we track

Check company identity source

Phase 2 3 trials

Drugs in these trials

Names as written in the registry records.

Latest recorded trial changes

Filters
Clear filters

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Adverse Events Description: Number of participants with adverse events Time frame: Through study completion, 43 days Measure: Vital Signs Description: Number of participants with abnormal vital signs Time frame: Through study completion, 43 days Measure: Laboratory Tests Description: Number of participants with abnormal laboratory tests Time frame: Through study completion, 43 days Measure: Glucose nadir after dosing Description: Time course of glucose concentrations during MMTT Time frame: 0-3 hours following liquid meal. After: Measure: Glucose Nadir Description: Each participant was treated for 7 days with either placebo or the indicated dose and regimen of mizagliflozin in a cross-over fashion. At the end of each 7 day treatment period participants were administered a mixed meal tolerance test. Glucose nadirs were derived from MMTT data for placebo and each mizagliflozin dose. Time frame: 0-3 hours following MMTT.

Check registry source